Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
Article has an altmetric score of 6

See more details

Referenced in 6 patents
110 readers on Mendeley
  • Article usage
  • Citations to this article (290)

Advertisement

Research Article Free access | 10.1172/JCI114234

A human 88-kD membrane glycoprotein (CD36) functions in vitro as a receptor for a cytoadherence ligand on Plasmodium falciparum-infected erythrocytes.

J W Barnwell, A S Asch, R L Nachman, M Yamaya, M Aikawa, and P Ingravallo

Department of Medical and Molecular Parasitology, New York University Medical School 10010.

Find articles by Barnwell, J. in: PubMed | Google Scholar

Department of Medical and Molecular Parasitology, New York University Medical School 10010.

Find articles by Asch, A. in: PubMed | Google Scholar

Department of Medical and Molecular Parasitology, New York University Medical School 10010.

Find articles by Nachman, R. in: PubMed | Google Scholar

Department of Medical and Molecular Parasitology, New York University Medical School 10010.

Find articles by Yamaya, M. in: PubMed | Google Scholar

Department of Medical and Molecular Parasitology, New York University Medical School 10010.

Find articles by Aikawa, M. in: PubMed | Google Scholar

Department of Medical and Molecular Parasitology, New York University Medical School 10010.

Find articles by Ingravallo, P. in: PubMed | Google Scholar

Published September 1, 1989 - More info

Published in Volume 84, Issue 3 on September 1, 1989
J Clin Invest. 1989;84(3):765–772. https://doi.org/10.1172/JCI114234.
© 1989 The American Society for Clinical Investigation
Published September 1, 1989 - Version history
View PDF
Abstract

Plasmodium falciparum-infected erythrocytes (IE) specifically adhere to vascular endothelium in vivo and to human endothelial cells, some human melanoma cell lines, and human monocytes in vitro. The tissue cell receptor for a ligand on the surface of the infected erythrocytes is an Mr 88,000 glycoprotein (GP88) recognized by the MAb OKM5, which also blocks cytoadherence of IE. Isolated, affinity-purified GP88 (CD36) competitively blocks cytoadherence and when absorbed to plastic surfaces, specifically binds P. falciparum IE. Additionally, monoclonal and polyclonal antibodies to GP88 block cytoadherence to both target cells and immobilized GP88. Binding to GP88 by IE is unaffected by the absence of calcium or the absence of thrombospondin, a putative mediator for cytoadherence of P. falciparum IE. Thus, GP88 (CD36), which has been demonstrated to be the same as platelet glycoprotein IV, interacts directly with P. falciparum IE, presumably via a parasite-induced ligand exposed on the surface of the infected erythrocytes. CD36 is shown to be present on brain endothelium in both individuals without malaria and individuals with cerebral malaria. This would suggest that factors other than just cerebral sequestration of IE play an initiating role in the genesis of cerebral malaria.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 765
page 765
icon of scanned page 766
page 766
icon of scanned page 767
page 767
icon of scanned page 768
page 768
icon of scanned page 769
page 769
icon of scanned page 770
page 770
icon of scanned page 771
page 771
icon of scanned page 772
page 772
Version history
  • Version 1 (September 1, 1989): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

Article has an altmetric score of 6
  • Article usage
  • Citations to this article (290)

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 6 patents
110 readers on Mendeley
See more details